eHealth told investors last quarter that the third quarter would be the bottom of its deliberate reset, the period of deepest marketing cuts and steepest declines in enrollments and revenue. The market appears to have taken that warning, and then some. Shares have collapsed more than 62% since the last report, trading at $0.53, a hair above the post-earnings low of $0.52 and roughly a third of the 200-day moving average. So the question for this report is less about whether the numbers look ugly, since management already promised they would. It is about whether the cash-flow and cost discipline behind the bridge-year strategy is holding up well enough to justify the pain.
Wall Street expects a loss of $0.82 per share on revenue of about $25.2 million. That revenue figure would be a 53% drop from the $53.9 million posted a year ago, an even sharper contraction than the 45% decline in the second quarter, which fits management's guidance that the year-over-year falloff would widen. The loss, meanwhile, is expected to narrow by about 43% from last year's $1.45 per share and improve on the second quarter's $1.18. That divergence is the heart of the story: eHealth is shrinking the top line on purpose while betting that lower acquisition spending and roughly $90 million in targeted variable and fixed savings will more than offset the lost volume.
Management held its full-year 2026 outlook for revenue, GAAP net income, adjusted EBITDA and operating cash flow last quarter, trimming only its expectations for tail revenue to roughly $20 million. A reaffirmation of that framework this time would be the cleanest validation. Operating cash flow deserves particular attention. The company generated $30.8 million in the first half and is targeting break-even or better for the year, and the third quarter, as the industry gears up for the annual enrollment period, is typically when cash starts flowing back out. A burn that looks manageable against the first-half cushion keeps the target credible. A larger drain would raise uncomfortable questions heading into the fourth quarter.
The lifetime advisory model is the other test. Last quarter brought early proof points, including a doubling of ancillary cross-sell rates and meaningful gains in Medicare Supplement and Part D lifetime values. Continued strength in those metrics, plus early traction for the newly launched final expense product, would suggest that fewer but more valuable customers can carry the business back to growth in 2027 as promised. Readiness for the enrollment season matters too, from the plan to have AI screen every incoming call to any updated read on carrier plan terminations and commission suppression, which management expected to run similar to slightly higher than last year. Any comments on the convertible preferred held by HIG, with its April 2027 date approaching, could move the stock as much as the quarter itself.
Sentiment remains slightly bearish, essentially unchanged from the prior quarter, but the share price tells a far gloomier story than the reaffirmed guidance would suggest. That gap cuts both ways. A trough quarter that lands as advertised, with cash flow on plan and guidance intact, could find a market braced for worse. But a weaker cash picture or any retreat from the full-year outlook would play directly into the fears that drove the selloff.
Ultimately, this report hinges on whether eHealth can show that the bottom it forecast is truly the bottom. If the cost savings, cash-flow trajectory and cross-sell economics are tracking with management's plan, the bridge-year narrative survives its toughest stretch. If not, the 2027 recovery story loses much of its foundation.